PubMed
MOTS-c is an ancient mitochondrial-encoded regulator of metabolic homeostasis
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 18% · Mixed 2% · Unfavorable overall 80%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2–3 mg · Most common: 5+ mg
Reports span 0.01 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 56% said they felt similar to their last entry, 31% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 44 days · Based on 45 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 25–50 mcg · Most common: 25–50 mcg
Reports span 0–400 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 89% said they felt similar to their last entry, 11% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 175 days · Based on 27 repeat reporters
Published sources linked on the MOTS-c and Oxytocin wiki pages.
PubMed
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015
PubMed
Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021
PubMed
Kim SJ, Xiao J, Wan J, et al. Aging Cell. 2019
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Zheng Y, Wei Z, Wang T. Frontiers in endocrinology. 2023
PubMed
Lee C, Kim KH, Cohen P. Free radical biology & medicine. 2016
PubMed
Striepens N, Kendrick KM, Maier W, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013
FDA Drug Label
Par Pharmaceutical. FDA Drug Label. 2014
PubMed
Heinrichs M, Baumgartner T, Kirschbaum C, et al. Biological psychiatry. 2003
PubMed
Yin H, Jiang M, Han T, et al. Peptides. 2024